D.E. Shaw & Co’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-930,726
| Closed | -$22.2M | – | 5187 |
|
|
2021
Q1 | $22.2M | Sell |
930,726
-95,494
| -9% | -$1.77M | 0.02% | 872 |
|
|
2020
Q4 | $15M | Buy |
1,026,220
+9,388
| +0.9% | +$124K | 0.01% | 1113 |
|
|
2020
Q3 | $14.4M | Sell |
1,016,832
-242,791
| -19% | -$3.71M | 0.01% | 1006 |
|
|
2020
Q2 | $18.5M | Buy |
1,259,623
+1,096,861
| +674% | +$11.1M | 0.02% | 822 |
|
|
2020
Q1 | $670K | Sell |
162,762
-474,397
| -74% | -$2.22M | ﹤0.01% | 3034 |
|
|
2019
Q4 | $3.06M | Buy |
637,159
+254,433
| +66% | +$1.4M | ﹤0.01% | 2135 |
|
|
2019
Q3 | $2.32M | Buy |
382,726
+105,373
| +38% | +$658K | ﹤0.01% | 2246 |
|
|
2019
Q2 | $1.8M | Sell |
277,353
-84,795
| -23% | -$597K | ﹤0.01% | 2310 |
|
|
2019
Q1 | $2.57M | Buy |
362,148
+9,184
| +3% | +$60.5K | ﹤0.01% | 1985 |
|
|
2018
Q4 | $1.72M | Buy |
352,964
+9,945
| +3% | +$51.8K | ﹤0.01% | 2277 |
|
|
2018
Q3 | $2.52M | Buy |
343,019
+114,693
| +50% | +$842K | ﹤0.01% | 2040 |
|
|
2018
Q2 | $1.46M | Buy |
228,326
+155,742
| +215% | +$1.03M | ﹤0.01% | 2450 |
|
|
2018
Q1 | $395K | Buy |
72,584
+50,009
| +222% | +$249K | ﹤0.01% | 3008 |
|
|
2017
Q4 | $94K | Sell |
22,575
-70,504
| -76% | -$424K | ﹤0.01% | 3496 |
|
|
2017
Q3 | $896K | Sell |
93,079
-161,303
| -63% | -$1.68M | ﹤0.01% | 2557 |
|
|
2017
Q2 | $3.01M | Buy |
254,382
+61,841
| +32% | +$791K | 0.01% | 1709 |
|
|
2017
Q1 | $2.47M | Buy |
192,541
+182,324
| +1,785% | +$2.19M | ﹤0.01% | 1706 |
|
|
2016
Q4 | $125K | Buy |
+10,217
| New | +$121K | ﹤0.01% | 3330 |
|
|
2016
Q1 | – | Sell |
-26,719
| Closed | -$207K | – | 3898 |
|
|
2015
Q4 | $207K | Buy |
26,719
+15,731
| +143% | +$121K | ﹤0.01% | 3545 |
|
|
2015
Q3 | $86K | Sell |
10,988
-25,731
| -70% | -$238K | ﹤0.01% | 3625 |
|
|
2015
Q2 | $333K | Sell |
36,719
-3,523
| -9% | -$35.5K | ﹤0.01% | 3374 |
|
|
2015
Q1 | $522K | Buy |
40,242
+28,778
| +251% | +$376K | ﹤0.01% | 3032 |
|
|
2014
Q4 | $156K | Sell |
11,464
-24,310
| -68% | -$272K | ﹤0.01% | 3852 |
|
|
2014
Q3 | $321K | Buy |
+35,774
| New | +$385K | ﹤0.01% | 3652 |
|
|
2013
Q3 | – | Sell |
-118,226
| Closed | -$1.22M | – | 4522 |
|
|
2013
Q2 | $1.22M | Buy |
+118,226
| New | +$1.63M | ﹤0.01% | 2542 |
|
D.E. Shaw & Co's GNMK Position: Q2 2021 in Review
D.E. Shaw & Co sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 930,726 shares — an estimated $22.2M sold.
D.E. Shaw & Co first reported a position in GNMK in Q2 2013 and held it in 25 quarters. The position peaked at $22.2M in Q1 2021. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- D.E. Shaw & Co reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- D.E. Shaw & Co sold 930,726 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $22.2M.
- D.E. Shaw & Co first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 25 quarters.
- D.E. Shaw & Co's GenMark Diagnostics, Inc position peaked at $22.2M in Q1 2021.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on D.E. Shaw & Co's 13F filing for Q2 2021, filed 16 Aug 2021.